Clinical trials: Elderly Infection
Hepatitis B, Hepatitis A
Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years
To evaluate the persistence of anti-hepatitis A virus (anti-HAV) and anti-hepatitis B surface antigen (anti-HBs) antibodies up to 6, 7, 8, 9 and 10 years after administration of the first dose of the study vaccine.
- Trial name
- NCT00197119
- Testing
- Twinrix™ Adult, Twinrix™ Junior
- Where
- 2 sites in Belgium, Czechia
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Infections, Rotavirus
Effectiveness of RotarixTM Vaccine in Children Aged Between 12 Weeks to < 5 Years, Hospitalised for Severe Gastroenteritis
This study aims to estimate the effectiveness of Rotarix™ vaccine against Rotavirus severe gastroenteritis (RV SGE) among hospitalised children aged between 12 weeks and < 5 years, in Venezuela and to assess the current disease…
- Trial name
- NCT01978223
- Testing
- Stool sample collection
- Sponsor
- GlaxoSmithKline
Herpes Zoster, mRNA Vaccine
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine
This clinical trial included two parts, Part A and Part B. The goal of Part A is to evaluate the safety and preliminary immunogenicity of the lyophilized herpes zoster virus mRNA vaccine (HZ mRNA vaccine) in healthy populations…
- Trial name
- NCT07400003
- Testing
- Low-dose experimental vaccine, High-dose experimental vaccine, Active-controlled vaccine A
- Where
- China
- Volunteers
- 519 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Norovirus Infections
A Study to Determine the Safety and Immunogenicity of Bivalent GI.1 and GII.4 Vaccines in Healthy Volunteers
This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and VXA-GII.4-NS co-administered (bivalent delivery) against a matching placebo arm.
- Trial name
- NCT05626803
- Testing
- Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose, Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose
- Where
- 3 sites in United States
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Vaxart
Herpes Zoster
A Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults
The purpose of the current ZOSTER-101 long-term follow-up (LTFU) study of ZOSTER-049 (NCT02723773) study, an extension of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) primary studies, is to assess the long-term vaccine…
- Trial name
- NCT05371080
- Testing
- HZ/su vaccine
- Where
- 107 sites in United States, Australia and 16 more
- Volunteers
- 3,038 people
- Sponsor
- GlaxoSmithKline
Hepatitis B
A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years
This study is conducted to assess safety and immunogenicity of GSK's HBsAg vaccine adjuvanted with GSK's AS37 adjuvant system in healthy, HBs naïve, adults aged 18-45 years and to differentiate GSK's AS37 adjuvant system from…
- Trial name
- NCT05561673
- Testing
- GSK's Hepatitis B vaccine adjuvanted with aluminum hydroxide, GSK's HBsAg candidate vaccine adjuvanted with GSK's AS03 adjuvant system, GSK's Hepatitis B vaccine adjuvanted with GSK's AS04 adjuvant system
- Where
- 5 sites in Belgium, Germany and 1 more
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)
This phase III clinical trial is an endpoint-driven randomized, double-blind, parallel-controlled, multicenter clinical trial, and around 13,000 subjects aged 18 years and above who have previously received 1 dose of…
- Trial name
- NCT05124561
- Testing
- Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- Volunteers
- healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Influenza
Study to Evaluate the Immunogenicity and Safety of 2 Formulations of GlaxoSmithKline (GSK) Biologicals' GSK1247446A Low Dose Influenza Vaccine Candidate
The purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to Fluarix™ administered intramuscularly in subjects aged 18-59 years
- Trial name
- NCT00374842
- Testing
- Fluarix™, GSK1247446A
- Where
- Belgium
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Orthomyxoviridae Infection, Influenza
Immunogenicity of Two Dosages of Inactivated, Split-Virion Influenza Vaccine Given by an Alternate Route in the Elderly
All marketed influenza vaccines are injected by the intramuscular route. This study will test whether an influenza vaccine is effective when injected by other route than into the muscle.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00296829
- Testing
- Inactivated, split-virion influenza vaccine
- Where
- 11 sites in Australia, New Zealand
- Volunteers
- 1,080 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Human
Efficacy Study With QIVc in Pediatric Subjects
This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age.
- Trial name
- NCT03932682
- Testing
- QIVc, Comparator
- Where
- 74 sites in Bangladesh, Bulgaria and 13 more
- Volunteers
- 5,723 people, healthy volunteers welcome
- Sponsor
- Seqirus
Pandemic Influenza Disease
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly Subjects
The present study aims to evaluate safety and immunogenicity of two doses, administered three weeks apart, of two influenza vaccines containing 7.5 micrograms or 15 micrograms of H5N1 influenza antigen, in non-elderly adult and…
- Trial name
- NCT00311480
- Testing
- Influenza vaccine surface antigen adjuvanted with MF59
- Where
- 4 sites in Italy
- Volunteers
- 520 people
- Sponsor
- Novartis
Varicella
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).
This study aims to assess the immunogenicity and safety of varicella vaccination in a population of autologous peripheral stem cell/ bone marrow transplantation recipients who have reached at least four months…
- Trial name
- NCT00792623
- Testing
- VarilrixTM
- Where
- 3 sites in Australia
- Volunteers
- 45 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
The Safety, Tolerance, and Immunogenicity of MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine (MER4101)
The purpose of this study is to evaluate the safety, tolerance, and immunogenicity of MAS-1-Adjuvanted seasonal inactivated influenza vaccine (IIV) (MER4101) with hemagglutinin dose escalation compared to non-adjuvanted…
- Trial name
- MER4101 (NCT02500680)
- Testing
- MER4101, Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Nova Immunotherapeutics Limited
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2010/2011
The purpose of the study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to WHO/EU recommendation for the 2010/2011 season for yearly licensing application.
- Trial name
- NCT01157702
- Testing
- Inactivated influenza vaccine (split virus, Vero cell-derived)
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Diphtheria, Tetanus
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents
The purpose of the study is to compare the immunogenicity and safety of a booster dose of BoostrixTM administered in a new syringe presentation to that of BoostrixTM administered in the previous syringe presentation in healthy…
- Conditions
- Diphtheria, Tetanus, Acellular Pertussis
- Trial name
- NCT01362322
- Testing
- Boostrix TM (new syringe presentation), Boostrix TM (previous syringe presentation)
- Where
- 3 sites in Chile, Mexico
- Volunteers
- 671 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers
The purpose of the study is to assess the efficacy and safety of CSL's 2009/2010 formulation of the Enzira vaccine.
- Trial name
- NCT00888381
- Testing
- Inactivated Influenza Vaccine (2009 / 2010 formulation)
- Where
- United Kingdom
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Seqirus
Hepatitis B
Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents
In this study the safety and immunogenicity of 2 different formulations of the candidate HBV-MPL vaccine administered according to a 0, 6-month schedule were explored and compared to that of Engerix™-B in healthy adolescents aged…
- Trial name
- NCT00697775
- Testing
- HBV-MPL vaccine Formulation A, HBV-MPL vaccine Formulation B, Engerix™-B
- Where
- Germany
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 1 to 6 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine in healthy children aged 1 to 6 years.
- Trial name
- NCT00161772
- Testing
- Tick-borne Encephalitis Vaccine
- Where
- 23 sites in Austria, Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
Influenza
Trial to Evaluate the Immunogenicity and Safety of Panblok® (H7 rHA) in Healthy Adults Aged 18 and Older
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Anhui/1/2013 (H7N9) administered at 3 dose levels in adjuvanted (SE) rHA formulations…
- Trial name
- PSC26 (NCT02464163)
- Testing
- Panblok, rHA adjuvant
- Where
- 9 sites in United States
- Volunteers
- 407 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Tick-borne Encephalitis
Dose-finding Study to Investigate the Safety and Immunogenicity of Two Vaccinations With FSME IMMUN NEW in Healthy Volunteers Aged 6 to 16 Years.
The purpose of this study is to investigate the safety and immunogenicity of three different concentrations of a TBE vaccine will be investigated in healthy children aged 6 to 16 years.
- Trial name
- NCT00161798
- Testing
- Tick-borne encephalitis vaccine
- Where
- 23 sites in Germany
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.